Synlogic, Inc.

NasdaqCM SYBX

Synlogic, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2024

Synlogic, Inc. Capital Expenditure is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Synlogic, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -518.00 K, a 34.68% change year over year.
Synlogic, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -793.00 K, a 64.63% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqCM: SYBX

Synlogic, Inc.

CEO	Mr. Antoine Awad
IPO Date	Sept. 30, 2015
Location	United States
Headquarters	301 Binney Street
Employees	6
Sector	Healthcare
Industries Biotechnology Clinical Trials Drugstores & Retail Pharmacies Pharmaceuticals

Description

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years